157 related articles for article (PubMed ID: 21304505)
21. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.
Podolanczuk A; Lazarus AH; Crow AR; Grossbard E; Bussel JB
Blood; 2009 Apr; 113(14):3154-60. PubMed ID: 19096013
[TBL] [Abstract][Full Text] [Related]
22. [Syk inhibitors].
Kimura Y; Chihara K; Takeuchi K; Sada K
Nihon Rinsho; 2013 Jul; 71(7):1248-52. PubMed ID: 23961675
[TBL] [Abstract][Full Text] [Related]
23. Deal watch: high hopes for oral SYK inhibitor in rheumatoid arthritis.
Flight MH
Nat Rev Drug Discov; 2012 Jan; 11(1):10. PubMed ID: 22212667
[No Abstract] [Full Text] [Related]
24. Kinase inhibitors for the treatment of rheumatoid arthritis.
Yazici Y; Steiger B
Bull NYU Hosp Jt Dis; 2012; 70(3):204-7. PubMed ID: 23259630
[TBL] [Abstract][Full Text] [Related]
25. Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib.
Boström E; Öhrn F; Hanze E; Sandström M; Martin P; Wählby-Hamrén U
J Clin Pharmacol; 2014 Dec; 54(12):1337-46. PubMed ID: 24895144
[TBL] [Abstract][Full Text] [Related]
26. Syk inhibitors.
Chihara K; Kimura Y; Honjo C; Takeuchi K; Sada K
Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(4):197-202. PubMed ID: 23994797
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Friedberg JW; Sharman J; Sweetenham J; Johnston PB; Vose JM; Lacasce A; Schaefer-Cutillo J; De Vos S; Sinha R; Leonard JP; Cripe LD; Gregory SA; Sterba MP; Lowe AM; Levy R; Shipp MA
Blood; 2010 Apr; 115(13):2578-85. PubMed ID: 19965662
[TBL] [Abstract][Full Text] [Related]
28. Kinase inhibitors: a new class of antirheumatic drugs.
Kyttaris VC
Drug Des Devel Ther; 2012; 6():245-50. PubMed ID: 23055694
[TBL] [Abstract][Full Text] [Related]
29. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes.
Cha HS; Boyle DL; Inoue T; Schoot R; Tak PP; Pine P; Firestein GS
J Pharmacol Exp Ther; 2006 May; 317(2):571-8. PubMed ID: 16452391
[TBL] [Abstract][Full Text] [Related]
30. Comment on "Therapeutic targeting of Syk in autoimmune diabetes".
Kapoor S
J Immunol; 2011 Feb; 186(4):1885; author reply 1886-5. PubMed ID: 21289311
[No Abstract] [Full Text] [Related]
31. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors.
Bonilla-Hernán MG; Miranda-Carús ME; Martin-Mola E
Rheumatology (Oxford); 2011 Sep; 50(9):1542-50. PubMed ID: 21622522
[TBL] [Abstract][Full Text] [Related]
32. The 2010 patent landscape for spleen tyrosine kinase inhibitors.
Moretto AF; Dehnhardt C; Kaila N; Papaioannou N; Thorarensen A
Recent Pat Inflamm Allergy Drug Discov; 2012 May; 6(2):97-120. PubMed ID: 22292554
[TBL] [Abstract][Full Text] [Related]
33. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels.
Leonhardt F; Zirlik K; Buchner M; Prinz G; Hechinger AK; Gerlach UV; Fisch P; Schmitt-Gräff A; Reichardt W; Zeiser R
Leukemia; 2012 Jul; 26(7):1617-29. PubMed ID: 22301676
[TBL] [Abstract][Full Text] [Related]
34. The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial.
Kitas GD; Abreu G; Jedrychowicz-Rosiak K; Miller JL; Nakov R; Panfilov S; Vencovsky J; Wang M; Weinblatt ME; White WB
J Am Soc Hypertens; 2014 Nov; 8(11):780-90. PubMed ID: 25455003
[TBL] [Abstract][Full Text] [Related]
35. [New biologic and non biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis].
Saito K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Jun; 32(3):149-59. PubMed ID: 19564711
[TBL] [Abstract][Full Text] [Related]
36. Back to the future: oral targeted therapy for RA and other autoimmune diseases.
O'Shea JJ; Laurence A; McInnes IB
Nat Rev Rheumatol; 2013 Mar; 9(3):173-82. PubMed ID: 23419429
[TBL] [Abstract][Full Text] [Related]
37. Novel small-molecular therapeutics for rheumatoid arthritis.
Fleischmann R
Curr Opin Rheumatol; 2012 May; 24(3):335-41. PubMed ID: 22357358
[TBL] [Abstract][Full Text] [Related]
38. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.
Pine PR; Chang B; Schoettler N; Banquerigo ML; Wang S; Lau A; Zhao F; Grossbard EB; Payan DG; Brahn E
Clin Immunol; 2007 Sep; 124(3):244-57. PubMed ID: 17537677
[TBL] [Abstract][Full Text] [Related]
39. The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Hilgendorf I; Eisele S; Remer I; Schmitz J; Zeschky K; Colberg C; Stachon P; Wolf D; Willecke F; Buchner M; Zirlik K; Ortiz-Rodriguez A; Lozhkin A; Hoppe N; von zur Muhlen C; zur Hausen A; Bode C; Zirlik A
Arterioscler Thromb Vasc Biol; 2011 Sep; 31(9):1991-9. PubMed ID: 21700926
[TBL] [Abstract][Full Text] [Related]
40. Syk kinase as a treatment target for therapy in autoimmune diseases.
Kyttaris VC; Tsokos GC
Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
